Study on the action of three kinds of anti-platelet drugs for in vitro inhibiting platelet activation
- VernacularTitle:三种抗血小板药物在体外对血小板活化的抑制作用研究
- Author:
Jianzhong WANG
;
Ling CAO
;
Jiaying YUAN
;
Shujuan WANG
- Publication Type:Journal Article
- Keywords:
Aspirin;
Platelet activation;
Flow cytometry
- From:
Chinese Journal of Laboratory Medicine
2001;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the action of aspirin, ticlopidine and cilostazol in inhibiting platelet activation in vitro. Methods Three kinds of anti platelet drugs, which inhibited the expression of fibrinogen receptor (FIB R) and P selectin (CD62P) on activated platelets surface in vitro, were analyzed by tri color flow cytometry. Results Three kinds of anti platelet drugs inhibited the expression of FIB R and CD62P on ADP activating platelet membrane surface differently. Cilostazol could inhibit the expression of FIB R and CD62P of the platelets markedly. Ticlopidine could inhibit the FIB R expression markedly, but CD62P indistinctly. Aspirin could not inhibit the expression of either FIB R and CD62P on ADP activating platelets. Conclusion Cilostazol is a strong anti platelet drug as compared with aspirin and ticlopidine. It could not only inhibit FIB R expression of activated platelets, which can prevent platelet aggregation, but also decrease the release reaction and procoagulative activities of activated platelets.
